INSILICO (03696.HK): Chairman launches share purchase plan in September, up to HKD 16 million
NewTimeSpace News: On 4 September 2026, InSilico Medicine (stock code: 03696) voluntarily announced that, based on confidence in the Company's future development prospects and recognition of its long-term investment value, Dr. Aleksandrs Zavoronkovs, chairman of the board, executive director, chief executive officer and chief business officer of the Company, has initiated a plan to purchase additional shares of the Company on the open market with his personal funds, subject to compliance with the Listing Rules and other applicable laws and regulations.
Under the plan, share purchases will be conducted during September 2026, with an estimated aggregate amount of up to HKD 16 million. Dr. Zavoronkovs previously invested in the Company's Series D financing in 2022.
According to the information available to the Company and to the best of the directors' knowledge and belief, if the purchase plan is implemented, the issued shares of the Company will continue to maintain a sufficient public float.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- INSILICO (03696.HK): Servier AI drug discovery milestone hit
- INSILICO (03696.HK): Nominates ISM9546 as 35th Preclinical Candidate
- INSILICO (03696.HK): Nominates GIPR antagonist ISM1354 as PCC
- INSILICO (03696.HK): Signs AI co-development deal worth up to tens of millions of USD
- INSILICO (03696.HK): Chairman increases shareholding by 113,500 shares, votable interest rises to approximately 8.02%
